In a development that matters to investors, employees, and patients across the United States, Bausch + Lomb disclosed on Monday that its chief executive, Brent Saunders, will depart the company following a mutual agreement with the board. The eye‑care manufacturer named its chairman, Thomas Appio, to serve as interim chief executive officer effective immediately.
Leadership transition and background
Saunders has led Bausch + Lomb since 2023, after previously serving as the company’s CEO from 2010 to 2013. Before rejoining Bausch + Lomb, he was the head of Allergan, guiding that firm through its $63 billion sale to AbbVie in 2020. The company did not provide a reason for Saunders’ departure, and Reuters’ request for comment was not answered at the time of publication.
Thomas Appio, who has been chairman of Bausch + Lomb’s parent, Bausch Health, since 2022, brings extensive experience to the role. He previously oversaw Bausch + Lomb’s international business and has been at the helm of Bausch Health for more than two years, positioning him to steer the company through this transitional period.
Financial outlook and upcoming forecasts
Citi noted that the timing of Saunders’ exit “seems sudden,” but emphasized that Appio’s long tenure with the company should provide stability. Both Bausch + Lomb and its parent, Bausch Health, expect to raise their 2026 adjusted EBITDA forecasts, excluding acquired research and development costs, based on preliminary third‑quarter results. The firms plan to release updated forecasts alongside their full third‑quarter earnings on October 28.
Current guidance for Bausch + Lomb’s full‑year adjusted EBITDA sits between $1.025 billion and $1.075 billion. The company’s performance is closely watched by investors because it operates in the growing eye‑care market, which includes contact lenses, surgical devices, and over‑the‑counter vision products.
Potential strategic implications
The leadership change arrives after a 2025 attempt to sell Bausch + Lomb that concluded without a deal. While the sale process did not materialize, the company remains a key asset for Bausch Health, which listed Bausch + Lomb as a separate entity in 2022 but retained controlling interest.
Analysts suggest that Appio’s interim tenure could focus on maintaining operational continuity, advancing product pipelines, and delivering on the revised earnings outlook. Should the company meet or exceed its updated EBITDA targets, it may strengthen its position for future strategic initiatives, whether that involves organic growth, further acquisitions, or renewed merger discussions.
What this means for stakeholders
Employees can expect a period of stability as Appio assumes day‑to‑day leadership while the board conducts a search for a permanent CEO. Customers and partners are likely to see no immediate disruption to product supply or service quality, given the continuity of senior management and the company’s robust operational framework.
Investors should monitor the October 28 earnings release for the revised guidance and any commentary from Appio regarding the company’s strategic direction. The market’s reaction will hinge on whether the updated EBITDA range reflects confidence in the firm’s growth prospects and its ability to navigate a competitive eye‑care landscape.
Conclusion
With Thomas Appio now at the helm on an interim basis, Bausch + Lomb is positioned to continue its focus on delivering innovative eye‑care solutions while aiming to improve its financial outlook for 2026. The company’s next earnings report will provide a clearer picture of how the leadership transition is influencing performance and shareholder value.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
